Kangfude Biotechnology

Wuhan Kangfude Biotechnology Co., Ltd. was founded in August 2010, with its headquarters located in the Biomedicine Park of Biolake in East Lake High-tech Development Zone, Wuhan. The company invested in CAPTOZYME in the United States, achieving synchronized research and development, production, and sales in China and the U.S. of foods, drugs, and kidney stone detection kits for the prevention of kidney stones. Related products will be launched first in the United States by the end of 2016 and in China in early 2017. The company was listed on the National Equities Exchange and Quotations (referred to as the "New Third Board") in March 2015, with the equity name "Kangfude" and equity code 832036. The enterprise was rated by the New Third Board Think Tank and Xinhua Net as 23rd overall in growth potential and 4th in the health and pharmaceutical field. The enterprise has been awarded multiple honorary titles including "National High-tech Enterprise" and "Technology Advanced Service Enterprise." CAPTOZYME also received a $2.5 million project research grant from the National Institutes of Health of the United States. Currently, there are 50 R&D personnel, all with bachelor's degrees or above. Among them are 4 returnee Ph.D.s with years of overseas protein drug R&D experience. The company's founder and key business personnel have repeatedly received talent program awards from governments at various levels, including the National "Thousand Talents Plan" and Hubei Province's "Hundred Talents Program." The enterprise has also received multiple government grants and awards, enabling rapid growth. The company is positioned to utilize resources from both China and the United States to explore the global market, becoming a large international enterprise with leading technology and internationally pioneering products, providing drugs and services for the global kidney stone-related disease market, and becoming a pioneer in non-invasive drug prevention and treatment of kidney stones.